Blog

Filter by:

post

291 FDA Complete Response Letters Decoded: Insights for Biologics CMC Strategy

post

Oral Drug Product Development of Small Molecules

post

Quality tools: Resources for Quality Control Specialists in Medical Writing

post

Why FDA PreCheck is a game-changer for small & mid-sized pharma — and how these companies should lean in

post

From Fast Track to PreCheck: A New Era in FDA Readiness Programs

post

The Startup’s Guide: 10 Must-Have CMC SOPs for Virtual Pharma in Phase 1

post

FDA PreCheck Pilot: A Smarter, Infrastructure-Centered Alternative to Fast Track and Breakthrough Designations

post

Why Strong Technical + Regulatory Alignment Matters

post

Managing Complexity: How Strategic Execution Drove a Cleanroom Upgrade Project to Completion

post

Building a QMS (Quality Management System) for Medical Device

post

Manufacturing Gaps in the U.S. Pharmaceutical Industry Exposed by Tariff Wars

post

The Real Cost of Uncertainty: Why On-Again, Off-Again Tariffs Hurt Biotech Supply Chains

post

Accelerating a Cytotoxic Peptide-Drug Conjugate to IND: A Medicinal Chemist’s Journey to IND with Syner-G BioPharma Group

post

Navigating Analytical Method Comparability and Equivalency Under ICH Q14: A New Era for Analytical Procedure Lifecycle Management

post

NextGen Lab Moves: Strategies to Maximize Your Laboratory Relocation Plan

post

Best Practices for System Evaluation and Selection

post

The U.S.-China Trade War and Its Impacts on Investigational Drug Supply Chains

post

Women’s History Month 2025

post

CFD Applications in Design of Manufacturing Processes and Facilities

post

Accelerating Cancer Treatment Approvals: The FDA’s Real-Time Oncology Review (RTOR) Program

post

The Evolution of US Biologic Drug Regulations

post

Navigating the Evolution from ICH Q2(R1) to ICH Q2(R2) and Implementation of ICH Q14 in Biopharmaceutical Method Validation

post

Project Orbis: Accelerating Global Access to Innovative Cancer Therapies

post

The Importance of Quality in Drug Development with Insights from the FDA Fiscal Year 2023 Report on the State of Pharmaceutical Quality